Enzyme‐Engineered Conjugated Polymer Nanoplatform for Activatable Companion Diagnostics and Multistage Augmented Synergistic Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Materials"
DOI: 10.1002/adma.202200062
Abstract: Companion diagnostics (CDx) provides critical information for precision medicine. However, current CDx is mostly limited to in vitro tests, which cannot accurately evaluate the disease progression and treatment response in real time. To overcome this… read more here.
Keywords: multistage; conjugated polymer; therapy; gox ... See more keywords
Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-018-2806-2
Abstract: Antibody therapy targeting specific molecules has been successfully used to treat various diseases including RCC, but some patients do not respond to the therapy (Motzer et al. 2015). There is an urgent need to develop… read more here.
Keywords: antibody therapy; rcc patients; develop companion; antibody ... See more keywords
Pretargeting in the context of theranostics and companion diagnostics in nuclear oncology
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Imaging"
DOI: 10.1007/s40336-018-0271-1
Abstract: PurposeThe concept of theranostics is well illustrated in nuclear oncology by radioactive iodide in thyroid diseases and by peptides or small molecular weight inhibitors in various cancers. It is also illustrated by radiolabeled antibodies, such… read more here.
Keywords: theranostics companion; nuclear oncology; pretargeting context; oncology ... See more keywords
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.06.008
Abstract: Somatic mutation in the epidermal growth factor receptor (EGFR) predict clinical response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) and is a promising target for personalised medicine. EGFR mutations have prognostic… read more here.
Keywords: egfr; egfr t790m; companion diagnostics; tyrosine kinase ... See more keywords
Implementing the EU in vitro diagnostic regulation – a European regulatory perspective on companion diagnostics
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Molecular Diagnostics"
DOI: 10.1080/14737159.2020.1720653
Abstract: With rapid advancements in medical science and technology, development of medicines moves ever more into the direction of personalized medicine; often referred to as targeted or precision medicines. The concept of personalized medicine is not… read more here.
Keywords: medicine; oncology; companion diagnostics; personalized medicine ... See more keywords
Abstract NT-099: NOVEL ANTIBODY DRUG CONJUGATE (ADC) AND COMPANION DIAGNOSTICS AGAINST CD248+ CANCER
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.ovcasymp18-nt-099
Abstract: Antibodies recognizing specific tumor targets can be used to deliver therapeutic payloads with high degree of specificity. The simultaneous use of antibody against same target for imaging and for therapy, an approach named “theranostics”, offers… read more here.
Keywords: companion diagnostics; antibody drug; tumor; cancer ... See more keywords